GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
T

Thor Medical A TRMED.OL · NOK

Health Care · Oslo Børs · 🇳🇴 Norway

Compare

4.09

-0.73%

Close of 9 Nov 2026, in NOK

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in NOK, from our data supplier.

FY2025

Revenue

NOK 439,000

FY2016FY2025

Net income

−NOK 58.0m

FY2016FY2025

Free cash flow

−NOK 120.6m

FY2016FY2025

Shareholders' equity

NOK 456.0m

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
RevenueNOK 439,000———————NOK 302,000NOK 314,000
Gross profit—−NOK 2.4m−NOK 331,000—−NOK 11.4m−NOK 14.9m—−NOK 222.3m——
Research and developmentNOK 2.1mNOK 3,309NOK 945,000—NOK 318.0mNOK 318.6mNOK 300.6mNOK 222.3m——
Operating income−NOK 69.7m−NOK 52.7m−NOK 7.3m−NOK 317.4m−NOK 447.6m−NOK 441.9m−NOK 440.4m−NOK 340.0m−NOK 316.5m−NOK 216.4m
Net income−NOK 58.0m−NOK 42.2m−NOK 26.6m−NOK 311.2m−NOK 441.3m−NOK 417.1m−NOK 433.6m−NOK 337.8m−NOK 293.8m−NOK 235.5m
Diluted earnings per share-0.24-0.18-0.11-2.68-1.86-1.76-1.83-1.42-1.24-0.99

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assetsNOK 708.6mNOK 414.4mNOK 330.8mNOK 109.6mNOK 296.7mNOK 314.6m—NOK 473.6mNOK 780.5mNOK 1.04bn
Cash and short-term investmentsNOK 179.3mNOK 123.4mNOK 41.3mNOK 96.6mNOK 276.7mNOK 292.9m————
Total liabilitiesNOK 252.6mNOK 77.3mNOK 58.9mNOK 45.8mNOK 156.2mNOK 135.9mNOK 4.6mNOK 110.4mNOK 100.9mNOK 95.5m
DebtNOK 159.2mNOK 737,000—NOK 159,000NOK 5.5mNOK 4.6mNOK 13.8m———
Shareholders' equityNOK 456.0mNOK 337.1mNOK 271.9mNOK 63.8mNOK 140.5mNOK 178.7m—NOK 363.2mNOK 679.6mNOK 949.3m
Shares outstanding237m237m234m116m237m237m237m237m237m237m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations−NOK 47.5m−NOK 23.7m−NOK 64.1m−NOK 409.1m−NOK 403.5m−NOK 398.2m−NOK 410.6m−NOK 326.6m−NOK 249.4m−NOK 204.0m
Capital spending−NOK 73.1m−NOK 100,000—−NOK 5.6m−NOK 259,000−NOK 185,000−NOK 1.1m−NOK 2.2m−NOK 2.5m−NOK 1.5m
Free cash flow−NOK 120.6m−NOK 23.8m−NOK 64.1m−NOK 414.7m−NOK 403.7m−NOK 398.4m−NOK 411.7m−NOK 328.8m−NOK 251.9m−NOK 205.5m

Latest quarters

By quarter end

Dec 2025Jun 2025Dec 2024Sept 2024Jun 2024Mar 2024Dec 2023Sept 2023
RevenueNOK 339,000NOK 100,000——————
Operating income−NOK 36.4m−NOK 33.3m−NOK 52.7m−NOK 52.7m−NOK 6,550−NOK 6,550−NOK 3,580−NOK 3,580
Net income−NOK 28.3m−NOK 29.7m−NOK 14,604−NOK 14,604−NOK 6,500−NOK 6,500−NOK 31−NOK 31
Diluted earnings per share-0.12-0.13-0.00-0.00-0.00-0.00-0.00-0.00
Cash from operations−NOK 47.0m−NOK 33.0m——————
Capital spending−NOK 73.0m−NOK 29.0m——————
Free cash flow−NOK 120.0m−NOK 62.0m——————
Total assetsNOK 708.6mNOK 561.0mNOK 414.4mNOK 414.4mNOK 320.1mNOK 320.1mNOK 330.8mNOK 330,835
Cash and short-term investmentsNOK 180.6mNOK 224.4mNOK 123.4mNOK 123.4mNOK 29.6mNOK 29.6mNOK 41.3mNOK 41,767
DebtNOK 159.2mNOK 8.7mNOK 1.2mNOK 437,000NOK 900,000NOK 400,000——
Shareholders' equityNOK 456.0mNOK 473.5mNOK 337.1mNOK 337.1mNOK 260.0mNOK 260.0mNOK 271.9mNOK 271,925

Financial ratios

Data as of 31 Oct 2026

FY2025FY2024FY2023FY2022FY2021FY2020
Operating margin-14047.2%—————
Net margin-13214.8%—————
Return on equity-12.7%-12.5%-9.8%-487.5%-314.1%-233.4%
Return on assets-8.2%-10.2%-8.0%-283.9%-148.8%-132.6%
Free cash flow yield—-2.5%—-86.6%——
Earnings growth37.4%58.9%-91.5%-29.5%5.8%—
Current ratio4.57x5.68x10.20x2.46x1.92x2.40x
Debt to equity0.00x0.00x0.00x0.00x0.08x0.02x
Equity ratio64.3%81.3%82.2%58.2%47.4%56.8%
Interest coverage-102.78x-0.45x——-1062.14x-882.57x
R&D as a share of sales468.6%—————
Buybacks as a share of market value—-1.6%-101.3%———

Growth per year

Compound annual rate

3 years5 years10 years
Revenue——-0.0%
Operating income-39.7%-30.9%-9.2%
Net income-42.9%-32.6%-10.4%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings-21.5-14.8-6.9-0.3-2.0-1.4-2.8-5.7-10.4-15.5

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.